alpha radiation (radiopharmaceutical)
Alpharadin is currently in clinical trials for bone metastases from prostate and breast cancer. Radium 223 is a one targeting isoptope which kills cancer cells using alpha radiation. The FDA has recently granted Alpharadin Fast Track designation. Bayer Healthcare plans to submit for approval to regulatory authorities in Europe and the USA mid-year 2012. Code in Other Therapy field until approved.
This drug should be coded